Cell Bio Human Tech셀바이오휴먼텍
318160 · KOSDAQ · ₩318160 · 셀바이오휴먼텍
₩6,100▼ ₩150 (2.40%)End-of-day · Oct 30, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
| Gross margin | 33.4% | 36.9% | 31.8% | 28.3% |
| Operating margin | 16.1% | 18.2% | 14.2% | 11.5% |
| Net margin | 17.3% | 17.1% | 15.4% | −6.8% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
| Revenue growth | +19.3% | +79.7% | +4.0% | — |
| Operating income growth | +4.9% | +130.8% | +28.2% | — |
| Net income growth | +21.2% | +99.2% | +335.8% | — |
Returns
| TTM | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
| Return on equity | 17.9% | 16.9% | 9.6% | −4.2% |
| Return on assets | 11.1% | 12.3% | 8.3% | −3.5% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
| Liabilities to equity | 44.7% | 49.9% | 14.0% | 19.4% |
| Net debt to equity | 13.4% | 5.8% | −22.9% | −17.1% |
| Current ratio | 286.6% | 229.3% | 381.8% | 314.5% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Cell Bio Human Tech / 셀바이오휴먼텍 / 318160 / KRX:318160
Source: KRX statistical information